Strong association between serum Vitamin D and Vaspin Levels, AIP, VAI and liver enzymes in NAFLD patients
Abstract
Abstract. Some studies indicated poor vitamin D level in NAFLD which is independently correlated with severity of steatosis. Low 25(OH) D3 levels are associated with an impaired lipid profile. Impaired levels and function of vaspin and omentin, which are adipokines, have been demonstrated in NAFLD patients. This study determined the relationship between vitamin D and serum liver enzymes, ultrasound findings, some adipokines, atherogenic index of plasma (AIP) and visceral adiposity index (VAI) in patients with NAFLD in a cross-sectional study. This study was a cross-sectional study in eighty-three NAFLD patients (57 males and 26 females). Plasma levels of omentin-1e-1, vaspin were measured. Anthropometric indices metabolic status was assessed. Visceral adiposity index and atherogenic index of plasma were calculated according to suggested formula. Anthropometric indices, lipid profiles, liver enzymes as well as abdominal ultrasonography and the status of vitamin D were assessed. The results showed that aspartate aminotransferase (AST) (44.22 ± 8.5 IU/L vs. 40.19 ± 8.75 IU/L, p-value = 0.039) AIP (0.767 ± 0.142 vs. 0.6417 ± 0.139, p < 0.001) and VAI (9.28 ± 3.25 vs. 7.048 ± 2.415, p = 0.001) were significantly higher in patients with vitamin D deficiency compared to those with vitamin D sufficiency. The positive correlations between Vaspin levels and vitamin D were found to be remarkably significant in both males and females (r = 0.437; P = 0.004; P < 0.001, r = −0.709, respectively. In both males and females serum vitamin D concentrations were negatively associated with AIP. Partial correlations controlling for age and sex showed that vitamin D is significantly and inversely associated with AIP, VAI, AST, and ALT. Additionally, vitamin D levels correlated directly with vaspin.
References
1 (2012) Vitamin D signalling in adipose tissue. British Journal of Nutrition. 108(11), 1915–1923.
2 (2015) High-dose vitamin D supplementation and liver histology in NASH. Gut. p. gutjnl-2015-310417
3 (2016) Vitamin D status and mortality: meta-analysis of individual participant data confirms strong association. Int. J. Vitam. Nutr. Res. 1, 4.
4 (2015) Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. Journal of Hepatology. 62(2), 405–411.
5 (2016) Assessment of Vitamin D status in a group of Egyptian children with non alcoholic fatty liver disease (multicenter study). Nutrition & Metabolism. 13(1), 53.
6 (2015) Relation between vitamin D status and nonalcoholic fatty liver disease in children. Journal of Pediatric Gastroenterology and Nutrition. 60(3), 396–404.
7 (2006) Alanine aminotransferase as a marker of non‐alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes/Metabolism Research and Reviews. 22(6), 437–443.
8 (2011) Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Digestive Diseases and Sciences. 56(7), 2124–2129.
9 (2014) Vitamin D status, liver enzymes, and incident liver disease and mortality: a general population study. Endocrine. 47(1), 213–220.
10 (2008) Adipokines and cytokines in non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 27(5), 412–421.
11 (2014) Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: Effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. Archives of Medical Research. 45(7), 589–595.
12 (2016) Nonalcoholic fatty liver disease and adipokines. Adipokines. 214.
13 (2016) Evaluation of the relation between vitamin D and serum omentin and vaspin levels in women. Experimental and Clinical Endocrinology & Diabetes. 124(07), 440–443.
14 (2011) Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism. 60(4), 544–549.
15 (2015) The protective functions of omentin in cardiovascular diseases. Clinica Chimica Acta. 448, 98–106.
16 (2010) Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes research and clinical practice. 88(1), 29–33.
17 (2013) Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases. 23(8), 792–798.
18 (2011) Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scandinavian Journal of Gastroenterology. 46(1), 91–97.
19 (2010) Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology. 45(2), 235–242.
20 (2013) Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association? Hepatology. 58(3), 1166–1174.
21 (2015) Vitamin D levels decline with rising number of cardiometabolic risk factors in healthy adults: association with adipokines, inflammation, oxidative stress and advanced glycation markers. PLoS One. 10(6), e0131753.
22 (2013) Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels—results from a randomized trial. European journal of internal medicine. 24(7), 644–649.
23 (2015) Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: A randomized placebo-controlled trial. Clinical Nutrition. 34(2), 201–206.
24 (2014) Association between vitamin D status and lipid profile in children and adolescents: a systematic review and meta-analysis. International Journal of Food Sciences and Nutrition. 65(4), 404–410.
25 (2011) Dietary reference intakes for calcium and vitamin D. National Academies Press.
26 (2011) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 53(3), 810–820.
27 (2011) Strong association between non alcoholic fatty liver disease (NAFLD) and low 25 (OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Medicine. 9(1), 1.
28 (2011) Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. Journal of Hepatology. 55(2), 415–425.
29 (2013) High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocrine Journal. 60(6), 743–752.
30 (2007) Associations between serum 25-hydroxyvitamin D 3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases. 17(7), 517–524.
31 (2014) Lower 25-hydroxyvitamin D3 levels and increased risk of liver diseases: is there a causal link? Endocrine. 47(1), 3–4.
32 (2014) Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine. 47(1), 70–80.
33 (2010) Low levels of 25‐hydroxyvitamin D3 in children with biopsy‐proven nonalcoholic fatty liver disease. Hepatology. 51(6), 2229.
34 (2013) Meta‐analysis: vitamin D and non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 38(3), 246–254.
35 (2013) Nonalcoholic fatty liver disease and reduced serum vitamin D3 levels. Metabolic Syndrome and Related Disorders. 11(4), 217–228.
36 (2016) 25-hydroxyvitamin D is associated with adiposity and cardiometabolic risk factors in a predominantly vitamin D-deficient and overweight/obese but otherwise healthy cohort. The Journal of Steroid Biochemistry and Molecular Biology.
37 (2010) Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes. 59(1), 242–248.
38 (2008) Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism. 57(2), 183–191.
39 (2004) Serum parathyroid hormone level is associated with body mass index. The 5th Tromso study. European Journal of Endocrinology. 151(2), 167–172.
40 (1988) Secondary hyperparathyroidism of morbid obesity regresses during weight reduction. Metabolism. 37(5), 425–428.
41 (2000) [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy]. Vnitrni lekarstvi. 46(3), 152–156.
42 (2016) The Associations of Serum Lipids with Vitamin D Status. PLoS One. 11(10), e0165157.
43 (2012) Serum 25 (OH) D is inversely associated with metabolic syndrome risk profile among urban middle-aged Chinese population. Nutrition Journal. 11(1), 1.
44 (2005) The possible role of Ca2+ on the activation of microsomal triglyceride transfer protein in rat hepatocytes. Biological and Pharmaceutical Bulletin. 28(8), 1418–1423.
45 (2009) Effect of calcium from dairy and dietary supplements on faecal fat excretion: a meta‐analysis of randomized controlled trials. Obesity Reviews. 10(4), 475–486.
46 (2015) Can skin exposure to sunlight prevent liver inflammation? Nutrients. 7(5), 3219–3239.
47 (2013) Vitamin D deficiency, insulin resistance, serum adipokine, and leptin levels in peritoneal dialysis patients. International Urology and Nephrology. 45(3), 879–884.
48 (2009) Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. European Journal of Endocrinology. 160(6), 965–971.
49 (2013) Emergence of omentin as a pleiotropic adipocytokine. Experimental and Clinical Endocrinology & Diabetes. 121(07), 377–383.
50 (2012) Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease. World J Gastroenterol. 18(46), 6790–6800.
